DDF 委员会 3 至 4 个月一轮：把排期当项目管理对象

1. Key takeaways

Final approval of device registration in Cambodia is made by the DDF committee meeting. The committee meets roughly every 3 to 4 months; if an application has not completed assessment before the current meeting, it is carried over to the next round. This mechanism means that Cambodia’s time cost is set by the committee window, not by the workload.

Public figures on the overall timeline conflict. The mainstream practitioner estimate is 12 to 18 calendar months. A government-level country profile states that registration usually takes 3 to 6 months and can extend to 10 months to 1 year when applications are concentrated; commercial sources quote 6 months and 4 to 6 months for Class A, among others. GRZAN does not endorse any single fixed figure; applicants are advised to model “committee window + carry-over risk” and to obtain written confirmation of the current estimate from DDF before submission.

GRZAN note: the DDF committee meeting cycle is roughly 3 to 4 months; reported timelines range from 3 to 6 months to 12 to 18 months — a spread of more than 4-fold — and no tiered timelines appear in the publicly readable official texts.

2. Legal basis

3. Expert insights

1. Carry-over, not slow review itself, is the main source of timeline uncertainty in Cambodia. One carry-over is 3 to 4 months. If the dossier is incomplete at first submission, a single deficiency round can skip two windows — 6 to 8 months. First-submission quality is therefore worth more in Cambodia than in most markets.

1. That no tiered timelines can be read from official texts is itself a fact that needs managing. Markets such as Thailand, Malaysia and Vietnam usually publish tiered review timelines; Cambodia does not. In project budgeting, applicants cannot assume “Class A is always faster than Class D”; they can only assume that both must pass the committee.

1. Cambodia hosting the 14th AMDC meeting signals rising regulatory activity. The 14th ASEAN Medical Device Committee meeting was held 19 to 22 August 2025 in Siem Reap, Cambodia. Hosting a regional meeting usually goes hand in hand with internal process consolidation; treat this as a signal of gradual formalisation, but do not extrapolate linearly to faster timelines.

4. Practical recommendations

1. Replace the day-countdown with a “window calendar”. Have the local entity confirm the actual meeting months of the three most recent committee meetings, draw a window calendar for the next 12 months, and then back-plan the three nodes — document freeze, submission, payment — onto that calendar.
2. Write deficiency-response speed into the service agreement. Because a deficiency round can skip a window, agree a response deadline with the local entity (for example, a written reply within 15 days of receiving a DDF query) and make it a measurable term.
3. Quote clients a range plus conditions, never a single point. For example: “assuming a complete first submission, 12 to 18 calendar months are expected; if assessment is not completed before the current committee meeting, the application is carried over to the next round.” Avoid single-point forecasts.

5. Verification checklist

• □ Actual meeting months of the three most recent committee meetings confirmed with the local entity
• □ Window calendar for the next 12 months drawn
• □ Document freeze, submission and payment back-planned onto the window calendar
• □ External timeline commitments phrased as “range + conditions”
• □ Deficiency-response deadline agreed in the local entity agreement
• □ Cambodia’s hosting of the 14th AMDC meeting recorded (19 to 22 August 2025, Siem Reap)

Regulatory information verified as of 29 October 2026.

In Southeast Asian markets, GRZAN’s core capabilities concentrate on three points. First, distinguishing the legislative progress of dedicated medical device laws across member states — Singapore, Malaysia, Thailand, Indonesia, the Philippines and Vietnam have each established written device regulatory frameworks, whereas Cambodia still has no dedicated Medical Device Law; the current rules are assembled from three layers: the registration-number legal basis provided by the 1996 Law on Drug Management and its 2007 amendment, the classification and procedures provided by Prakas No. 1258 of 2012, and the technical framework provided by the ASEAN Medical Device Directive. Compliance certainty is therefore markedly lower than in markets that have completed legislation. Second, local authorised representative services: GRZAN can act as the manufacturer’s statutory representative in Cambodia, undertaking registration submission, regulatory communication and post-market reporting obligations, and assisting with the practical requirements for a Cambodian registered pharmacist and a drug import-export enterprise licence. Third, quality system and testing support: helping establish a quality management system that meets ISO 13485 requirements and organising the technical dossier under the ASEAN Common Submission Dossier Template (CSDT).

Business enquiries: info@grzanglobal.com